Review

Modes of action of TLR7 agonists in cancer therapy

*Author for correspondence:

E-mail Address: Sebastian.kobold@med.uni-muenchen.de

Center of Integrated Protein Science Munich (CIPS-M) & Division of Clinical Pharmacology, Department of Internal Medicine IV, Ludwig-Maximilians-Universität München, Munich, Germany

Search for more papers by this author

Gabriela Wiedemann

Center of Integrated Protein Science Munich (CIPS-M) & Division of Clinical Pharmacology, Department of Internal Medicine IV, Ludwig-Maximilians-Universität München, Munich, Germany

Search for more papers by this author

Simon Rothenfußer

Center of Integrated Protein Science Munich (CIPS-M) & Division of Clinical Pharmacology, Department of Internal Medicine IV, Ludwig-Maximilians-Universität München, Munich, Germany

Search for more papers by this author

Stefan Endres

Center of Integrated Protein Science Munich (CIPS-M) & Division of Clinical Pharmacology, Department of Internal Medicine IV, Ludwig-Maximilians-Universität München, Munich, Germany

Search for more papers by this author

Published Online:27 Nov 2014https://doi.org/10.2217/imt.14.75

View article

Abstract

From the numerous Toll-like receptor agonists, only TLR7 agonists have been approved for cancer treatment, although they are current restricted to topical application. The main target cells of TLR7 agonists are plasmacytoid dendritic cells, producing IFN-α and thus acting on other immune cells. Thereby dendritic cells acquire enhanced costimulatory and antigen-presenting capacity, priming an adaptive immune response. Besides NK cells, antigen-specific T cells are the main terminal effectors of TLR7 agonists in tumor therapy. This qualifies TLR7 agonists as vaccine adjuvants, which is currently being tested in clinical trials. However, the systemic application of TLR7 agonists shows insufficient efficacy, most likely owing to toxicity-limited dosing. The use of TLR7 agonists in combinational therapy holds the promise of synergistic activity and lower required doses.

Keywords:

Papers of special note have been highlighted as: •• of considerable interest

References

1 Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature 351(6325), 355–356 (1991).Crossref, Medline, CAS, Google Scholar
2 Roach JC, Glusman G, Rowen L et al. The evolution of vertebrate Toll-like receptors. Proc. Natl. Acad. Sci. USA 102(27), 9577–9582 (2005).Crossref, Medline, CAS, Google Scholar
3 Uematsu S, Akira S. Toll-like receptors and innate immunity. J. Mol. Med. (Berl.) 84(9), 712–725 (2006).Crossref, Medline, CAS, Google Scholar
4 Vacchelli E, Eggermont A, Sautes-Fridman C et al. Trial watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2(8), e25238 (2013).•• Excellent review on TLRs for cancer therapy.Crossref, Medline, Google Scholar
5 Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64(3), 529–564 (1994).Crossref, Medline, CAS, Google Scholar
6 Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 51(10), 2524–2530 (1991).Medline, CAS, Google Scholar
7 Witt PL, Ritch PS, Reding D et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res. 53(21), 5176–5180 (1993).Medline, CAS, Google Scholar
8 Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471–484 (2006).Crossref, Medline, CAS, Google Scholar
9 Dudek AZ, Yunis C, Harrison LI et al. First in human Phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13(23), 7119–7125 (2007).Crossref, Medline, CAS, Google Scholar
10 Holldack J. Toll-like receptors as therapeutic targets for cancer. Drug Discov Today 19(4), 379–382 (2013).Crossref, Medline, Google Scholar
11 Bourquin C, Hotz C, Noerenberg D et al. Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res. 71(15), 5123–5133 (2011).Crossref, Medline, CAS, Google Scholar
12 Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. Dermatol. Surg. 39(9), 1306–1316 (2013).Crossref, Medline, CAS, Google Scholar
13 Arits AH, Mosterd K, Essers BA et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 14(7), 647–654 (2013).Crossref, Medline, CAS, Google Scholar
14 Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian Toll-like receptors: gene structure, expression, and evolution. Eur. Cytokine Netw. 11(3), 362–371 (2000).Medline, CAS, Google Scholar
15 Adams S, Kozhaya L, Martiniuk F et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin. Cancer Res. 18(24), 6748–6757 (2012).Crossref, Medline, CAS, Google Scholar
16 Geller MA, Cooley S, Argenta PA et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol. Immunother. 59(12), 1877–1884 (2010).Crossref, Medline, CAS, Google Scholar
17 Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18(8), 1254–1261 (2012).Crossref, Medline, CAS, Google Scholar
18 Hornung V, Guenthner-Biller M, Bourquin C et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11(3), 263–270 (2005).Crossref, Medline, CAS, Google Scholar
19 Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol. Rev. 243(1), 61–73 (2011).Crossref, Medline, CAS, Google Scholar
20 Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J. Int. Med. 265(1), 43–57 (2009).Crossref, Medline, CAS, Google Scholar
21 Engel AL, Holt GE, Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Exp. Rev. Clin. Pharm. 4(2), 275–289 (2011).Crossref, Medline, CAS, Google Scholar
22 Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196–200 (2002).•• Excellent article on TLR7 signaling.Crossref, Medline, CAS, Google Scholar
23 Applequist SE, Wallin RP, Ljunggren HG. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 14(9), 1065–1074 (2002).Crossref, Medline, CAS, Google Scholar
24 Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of Toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168(9), 4531–4537 (2002).Crossref, Medline, CAS, Google Scholar
25 Edwards AD, Diebold SS, Slack EM et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33(4), 827–833 (2003).Crossref, Medline, CAS, Google Scholar
26 Poovassery JS, Bishop GA. Type I IFN receptor and the B cell antigen receptor regulate TLR7 responses via distinct molecular mechanisms. J. Immunol. 189(4), 1757–1764 (2012).Crossref, Medline, CAS, Google Scholar
27 Clingan JM, Matloubian M. B Cell-intrinsic TLR7 signaling is required for optimal B cell responses during chronic viral infection. J. Immunol. 191(2), 810–818 (2013).Crossref, Medline, CAS, Google Scholar
28 Bekeredjian-Ding IB, Wagner M, Hornung V et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174(7), 4043–4050 (2005).Crossref, Medline, Google Scholar
29 Alexopoulou L, Desnues B, Demaria O. [Toll-like receptor 8: the awkward TLR]. Med. Sci. (Paris) 28(1), 96–102 (2012).Crossref, Medline, Google Scholar
30 Cervantes JL, Weinerman B, Basole C, Salazar JC. TLR8: the forgotten relative revindicated. Cell. Mol. Immunol. 9(6), 434–438 (2012).Crossref, Medline, CAS, Google Scholar
31 Crozat K, Vivier E, Dalod M. Crosstalk between components of the innate immune system: promoting anti-microbial defenses and avoiding immunopathologies. Immunol. Rev. 227(1), 129–149 (2009).Crossref, Medline, CAS, Google Scholar
32 Janke M, Poth J, Wimmenauer V et al. Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8. J. Allerg. Clin. Immunol. 123(5), 1026–1033 (2009).Crossref, Medline, CAS, Google Scholar
33 Ablasser A, Poeck H, Anz D et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J. Immunol. 182(11), 6824–6833 (2009).Crossref, Medline, CAS, Google Scholar
34 Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13(8), 859–875 (2008).Crossref, Medline, CAS, Google Scholar
35 Liu J, Xu C, Hsu LC, Luo Y, Xiang R, Chuang TH. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol. Immunol. 47(5), 1083–1090 (2010).Crossref, Medline, CAS, Google Scholar
36 Gorden KK, Qiu X, Battiste JJ, Wightman PP, Vasilakos JP, Alkan SS. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J. Immunol. 177(11), 8164–8170 (2006).Crossref, Medline, CAS, Google Scholar
37 Meier A, Chang JJ, Chan ES et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat. Med. 15(8), 955–959 (2009).Crossref, Medline, CAS, Google Scholar
38 Torcia MG, Nencioni L, Clemente AM et al. Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males. PLoS ONE 7(6), e39853 (2012).Crossref, Medline, CAS, Google Scholar
39 Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 177(4), 2088–2096 (2006).Crossref, Medline, Google Scholar
40 Seillet C, Laffont S, Tremollieres F et al. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. Blood 119(2), 454–464 (2012).Crossref, Medline, CAS, Google Scholar
41 Han JH, Park SY, Kim JB et al. TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells. Am. J. Reprod. Immunol. 70(4), 317–326 (2013).Crossref, Medline, CAS, Google Scholar
42 Kang S-J, Tak J-H, Cho J-H, Lee H-J, Jung Y-J. Stimulation of the endosomal TLR pathway enhances autophagy-induced cell death in radiotherapy of breast cancer. Genes Genomics 32(6), 599–606 (2010).Crossref, CAS, Google Scholar
43 Cherfils-Vicini J, Platonova S, Gillard M et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest. 120(4), 1285–1297 (2010).•• Excellent article showing that TLR7 may also be disease promoting.Crossref, Medline, CAS, Google Scholar
44 Ochi A, Graffeo CS, Zambirinis CP et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J. Clin. Invest. 122(11), 4118–4129 (2012).Crossref, Medline, CAS, Google Scholar
45 Smith EB, Schwartz M, Kawamoto H et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J. Urol. 177(6), 2347–2351 (2007).Crossref, Medline, CAS, Google Scholar
46 Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk. Lymphom. 46(6), 935–939 (2005).Crossref, Medline, Google Scholar
47 Smits EL, Cools N, Lion E et al. The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol. Immunother. 59(1), 35–46 (2010).Crossref, Medline, CAS, Google Scholar
48 Bao M, Liu YJ. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell 4(1), 40–52 (2013).Crossref, Medline, CAS, Google Scholar
49 Yang Y, Liu B, Dai J et al. Heat shock protein gp96 is a master chaperone for Toll-like receptors and is important in the innate function of macrophages. Immunity 26(2), 215–226 (2007).Crossref, Medline, Google Scholar
50 Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 452(7184), 234–238 (2008).Crossref, Medline, CAS, Google Scholar
51 Ewald SE, Engel A, Lee J, Wang M, Bogyo M, Barton GM. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J. Exp. Med. 208(4), 643–651 (2011).Crossref, Medline, CAS, Google Scholar
52 Li L, Cousart S, Hu J, McCall CE. Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells. J. Biol. Chem. 275(30), 23340–23345 (2000).Crossref, Medline, CAS, Google Scholar
53 Lin SC, Lo YC, Wu H. Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling. Nature 465(7300), 885–890 (2010).Crossref, Medline, CAS, Google Scholar
54 Kawai T, Sato S, Ishii KJ et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5(10), 1061–1068 (2004).Crossref, Medline, CAS, Google Scholar
55 Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398(6724), 252–256 (1999).Crossref, Medline, CAS, Google Scholar
56 Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell. 14(3), 289–301 (2004).Crossref, Medline, CAS, Google Scholar
57 Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J. Clin. Invest. 107(1), 13–19 (2001).Crossref, Medline, CAS, Google Scholar
58 Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174(3), 1259–1268 (2005).Crossref, Medline, CAS, Google Scholar
59 Drobits B, Holcmann M, Amberg N et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 122(2), 575–585 (2012).Crossref, Medline, CAS, Google Scholar
60 Urosevic M, Oberholzer PA, Maier T et al. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin. Cancer Res. 10(15), 4959–4970 (2004).Crossref, Medline, CAS, Google Scholar
61 Tel J, Sittig SP, Blom RA et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol. 191(10), 5005–5012 (2013).Crossref, Medline, CAS, Google Scholar
62 Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J. Cut. Pathol. 32(4), 257–262 (2005).Crossref, Medline, Google Scholar
63 Koga-Yamakawa E, Dovedi SJ, Murata M et al. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int. J. Cancer 132(3), 580–590 (2013).Crossref, Medline, CAS, Google Scholar
64 Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 115(10), 1949–1957 (2010).Crossref, Medline, CAS, Google Scholar
65 Inglefield JR, Dumitru CD, Alkan SS et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J. Interferon Cytokine Res. 28(4), 253–263 (2008).Crossref, Medline, CAS, Google Scholar
66 Le Mercier I, Poujol D, Sanlaville A et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 73(15), 4629–4640 (2013).Crossref, Medline, CAS, Google Scholar
67 Pantel A, Teixeira A, Haddad E, Wood EG, Steinman RM, Longhi MP. Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol. 12(1), e1001759 (2014).Crossref, Medline, Google Scholar
68 Ito T, Amakawa R, Kaisho T et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 195(11), 1507–1512 (2002).Crossref, Medline, CAS, Google Scholar
69 Tel J, Schreibelt G, Sittig SP et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8⁺ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121(3), 459–467 (2013).Crossref, Medline, CAS, Google Scholar
70 Beck B, Dorfel D, Lichtenegger FS et al. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9, 151 (2011).Crossref, Medline, CAS, Google Scholar
71 Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171(11), 6275–6282 (2003).Crossref, Medline, CAS, Google Scholar
72 Prins RM, Craft N, Bruhn KW et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. 176(1), 157–164 (2006).Crossref, Medline, CAS, Google Scholar
73 Hong X, Dong T, Hu J et al. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. Int. J. Col. Dis. 28(1), 25–33 (2013).Crossref, Medline, Google Scholar
74 Dhodapkar MV, Sznol M, Zhao B et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci. Transl. Med. 6(232), 232ra251 (2014).Crossref, Google Scholar
75 Fehres CM, Bruijns SC, Van Beelen AJ et al. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8 T-cell cross-priming. Eur. J. Immunol. 44(8), 2145–2124 (2014).Crossref, Google Scholar
76 Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204(6), 1441–1451 (2007).Crossref, Medline, CAS, Google Scholar
77 Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J. Immunol. 188(4), 1583–1591 (2012).Crossref, Medline, CAS, Google Scholar
78 Bourquin C, Schmidt L, Lanz AL et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J. Immunol. 183(10), 6078–6086 (2009).Crossref, Medline, CAS, Google Scholar
79 Chuang CM, Monie A, Hung CF, Wu TC. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J. Biomed. Sci. 17, 32 (2010).Crossref, Medline, Google Scholar
80 Dumitru CD, Antonysamy MA, Gorski KS et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol. Immunother. 58(4), 575–587 (2009).Crossref, Medline, CAS, Google Scholar
81 Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J. Immunotoxicol. 6(4), 257–265 (2009).Crossref, Medline, CAS, Google Scholar
82 Wysocka M, Newton S, Benoit BM et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin. Lymphoma Myeloma 7(8), 524–534 (2007).Crossref, Medline, CAS, Google Scholar
83 Grela F, Aumeunier A, Bardel E et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma. J. Immunol. 186(1), 284–290 (2011).Crossref, Medline, CAS, Google Scholar
84 Dummer R, Hauschild A, Becker JC et al. An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14(3), 856–864 (2008).Crossref, Medline, CAS, Google Scholar
85 Morse MA, Chapman R, Powderly J et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 17(14), 4844–4853 (2011).Crossref, Medline, CAS, Google Scholar
86 Huang SJ, Hijnen D, Murphy GF et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J. Invest. Dermatol. 129(11), 2676–2685 (2009).Crossref, Medline, CAS, Google Scholar
87 Lu H, Wagner WM, Gad E et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J. Immunol. 184(9), 5360–5367 (2010).Crossref, Medline, CAS, Google Scholar
88 Narayan R, Nguyen H, Bentow JJ et al. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J. Invest. Dermatol. 132(1), 163–169 (2012).Crossref, Medline, CAS, Google Scholar
89 Xiong Z, Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J. Immunother. 34(3), 264–269 (2011).Crossref, Medline, CAS, Google Scholar
90 Bourquin C, Wurzenberger C, Heidegger S et al. Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. J. Immunother. 33(9), 935–944 (2010).Crossref, Medline, CAS, Google Scholar
91 Dang Y, Wagner WM, Gad E et al. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin. Cancer Res. 18(11), 3122–3131 (2012).Crossref, Medline, CAS, Google Scholar
92 Bourquin C, Schmidt L, Hornung V et al. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood 109(7), 2953–2960 (2007).Crossref, Medline, CAS, Google Scholar
93 Goldinger SM, Dummer R, Baumgaertner P et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(⁺) T-cell responses in melanoma patients. Eur. J. Immunol. 42(11), 3049–3061 (2012).Crossref, Medline, CAS, Google Scholar
94 Broomfield SA, Van Der Most RG, Prosser AC et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 182(9), 5217–5224 (2009).Crossref, Medline, CAS, Google Scholar
95 Ma F, Zhang J, Zhang J, Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell. Mol. Immunol. 7(5), 381–388 (2010).Crossref, Medline, CAS, Google Scholar
96 Fiorenza S, Kenna TJ, Comerford I et al. A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin. J. Immunol. 189(12), 5622–5631 (2012).Crossref, Medline, CAS, Google Scholar
97 Clark RA, Huang SJ, Murphy GF et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J. Exp. Med. 205(10), 2221–2234 (2008).Crossref, Medline, CAS, Google Scholar
98 Aranda F, Llopiz D, Diaz-Valdes N et al. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res. 71(9), 3214–3224 (2011).Crossref, Medline, CAS, Google Scholar
99 Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, Radsak MP. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin. Rev. Allerg. Immunol. 32(1), 57–66 (2007).Crossref, Medline, Google Scholar
100 Fotin-Mleczek M, Duchardt KM, Lorenz C et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1–15 (2011).Crossref, Medline, CAS, Google Scholar
101 Adams S, O'Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181(1), 776–784 (2008).Crossref, Medline, CAS, Google Scholar
102 Bishop GA, Hsing Y, Hostager BS, Jalukar SV, Ramirez LM, Tomai MA. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol. 165(10), 5552–5557 (2000).Crossref, Medline, CAS, Google Scholar
103 Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell. Immunol. 203(1), 55–65 (2000).Crossref, Medline, CAS, Google Scholar
104 Green NM, Laws A, Kiefer K et al. Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J. Immunol. 183(3), 1569–1576 (2009).Crossref, Medline, CAS, Google Scholar
105 Shi Y, White D, He L, Miller RL, Spaner DE. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res. 67(4), 1823–1831 (2007).Crossref, Medline, CAS, Google Scholar
106 Wolska A, Cebula-Obrzut B, Smolewski P, Robak T. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. Leuk. Lymph. 54(6), 1268–1278 (2013).Crossref, Medline, CAS, Google Scholar
107 Spaner DE, Shi Y, White D et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 20(2), 286–295 (2006).Crossref, Medline, CAS, Google Scholar
108 Wang D, Precopio M, Lan T et al. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol. Cancer Ther. 9(6), 1788–1797 (2010).Crossref, Medline, CAS, Google Scholar
109 Shojaei H, Oberg HH, Juricke M et al. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res. 69(22), 8710–8717 (2009).Crossref, Medline, CAS, Google Scholar
110 Adlard AL, Dovedi SJ, Telfer BA et al. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int. J. Cancer 135(4), 820–829 (2014).Crossref, Medline, CAS, Google Scholar
111 Dewan MZ, Vanpouille-Box C, Kawashima N et al. Synergy of topical Toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin. Cancer Res. 18(24), 6668–6678 (2012).Crossref, Medline, CAS, Google Scholar
112 Dovedi SJ, Melis MH, Wilkinson RW et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 121(2), 251–259 (2013).Crossref, Medline, CAS, Google Scholar
113 Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother. 33(3), 225–235 (2010).Crossref, Medline, CAS, Google Scholar
114 Lanford RE, Guerra B, Chavez D et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology (7), 1508–1517, 1517.e1–10 (2013).Crossref, Medline, Google Scholar

Vol. 6, No. 10

Metrics

Downloaded 605 times

History

Published online 27 November 2014

Published in print October 2014

Information

Keywords

Financial & competing interests disclosure

S Kobold and S Endres are supported by the Munich biotech cluster m4, by a grant from 4SC (Munich), by the melanoma research alliance (grant number N269626), by the Graduiertenkolleg 1202 'Oligonucleotides in cell biology and therapy' funded by the Deutsche Forschungsgemeinschaft and by the training network 'i-Target' funded by the elite network of Bavaria. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download